From WisPolitics.com/WisBusiness.com …
— Cellectar Biosciences, a drug development firm that spun off from UW-Madison, is touting “compelling” new data on the effectiveness of its cancer therapy.
The company yesterday showcased the results in a presentation at the American Society of Clinical Oncology Annual Meeting in Chicago. The data came from its Phase 2 clinical trial for iopofosine 131, which is used to deliver a targeted radioisotope to treat specific cancers.
The results “demonstrated significant efficacy” for the 24-person study group, which included patients treated with Cellectar’s drug following a different treatment with post-Bruton Tyrosine Kinase inhibitor, or BTKi therapy.
Jarrod Longcor, chief operating officer for the company, says these patients “represent a distinct clinical population” within those with Waldenström macroglobulinemia, a rare form of blood cancer. They face limited treatment response and “rapid disease progression” following the end of BTKi therapy, according to Longcor.
“We are highly encouraged by these results … which demonstrate compelling efficacy and durable responses,” he said, noting they were seen even in this “particularly challenging patient population” that has progressed following earlier therapy.
Yesterday’s presentation highlighted the trial’s 100% clinical benefit rate and 87.5% overall response rate, as well as the 79.2% major response rate, indicating a partial response or better.
President and CEO James Caruso says the company plans to pursue accelerated approval in the United States and start a Phase 3 study later this year to confirm its findings.
“We remain committed to bringing iopofosine to the thousands of patients who may benefit from this therapy,” he said in a statement.
See the release below.
For more of the latest news on the state economy and Wisconsin businesses from startups to industry leaders, sign up today for a free two-week trial of the daily morning news report from WisBusiness.com.
Top Stories
– 5 American cruise ship passengers leave Nebraska quarantine facility
– As Ebola Spreads, Scientists Race to Find Vaccines and Treatments
– Focused on Work, Needed at Home: A Federal Caregiving Policy Might Help
– US CDC flags health risks linked to travel-related cosmetic procedures
– Tracking U.S. Measles 2026: 1,900 Cases Put Elimination Status at Risk
– Festering Infections to Untreated Cancer: ICE Detainees Describe Medical Neglect Across US
– Celcuity plunges after experimental breast cancer treatment data disappoints
Press Releases
– UW Health: Now offers next-day home delivery for prescriptions
